Yttrium-90 is produced by the nuclear decay of strontium-90 which has a half-life of nearly 29 years and is a fission product of uranium used in nuclear reactors.

Yttrium-90 is a radioisotope of the chemical element yttrium, which, in addition to the element-specific 39 protons, has 51 neutrons in the atomic nucleus, resulting in the mass number 90. The radioactive 90 Y nuclide is used in medicine in the radiation therapy of certain types of cancer (see below). See also: list of Yttrium isotopes.

Feb 5, 2019 · 90Y is a pure beta-emitter with a half-life of 64.04 hours that dis-integrates into stable zirconium-90 (90Zr) by emitting beta particles with a maximum energy of 2.27 MeV and an average energy of 0.937 MeV. Within soft tissue, the released beta energy has a maximum penetration range of 11 mm with an average range of 2.5 mm.

Aug 5, 2023 · Yttrium-90 (90Y) is a radioisotope derived from the decay of 90 Sr. Yttrium-90 decays due to the emission of β- particles, with a half-life of 2.67 days 5. It has no gamma energy emission, but may be imaged through the use of bremsstrahlung interactions with planar or SPECT imaging.

All the other isotopes have half-lives of less than a day, except 87 Y, which has a half-life of 79.8 hours, and 90 Y, with 64 hours. The dominant decay mode below the stable 89 Y is electron capture and the dominant mode after it is beta emission. Thirty-five …

Nov 20, 2024 · Yttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer. Yttrium Y-90 is radioactive isotope of yttrium. A beta/gamma-emitter with a half life of 2.7 days. yttrium-90. Computed by Lexichem TK 2.7.0 (PubChem release 2024.11.20) InChI=1S/Y/i1+1. Computed by InChI 1.07.0 (PubChem release 2024.11.20)

This paper overviews Yttrium-90 (90Y) as a theranostic and nuclear medicine imaging of 90Y radioactivity with bremsstrahlung imaging and positron emission tomography. In addition, detection and optical imaging of 90Y radioactivity using Cerenkov ...

Y-90 is artificially produced as a decay product of strontium-90 or through neutron irradiation of yttrium-89 in nuclear reactors. Its radiation characteristics make it valuable for medical and industrial applications. Y-90 is widely used in medicine, particularly in cancer treatment.

During SIRT, millions of yttrium-90 (90 Y)-radiolabeled microspheres are injected into the hepatic arteries preferentially depositing into tumors because of their increased vascularity, with the goal of delivering lethal doses of radiation to tumors but sublethal doses to normal parenchyma.

Nowadays, mainly three oncological therapies exploit the intrinsic emissive characteristic of (90)Y. Radionuclide therapies include peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumour (NET) treatment, radioimmunotherapy (RIT) in non-Hodgkin's lymphoma (NHL) treatment and transarterial radioembolization therapy (TARET) in unrese...